Singular Genomics Systems

Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. It develops two integrated solutions: G4 Instrument and PX Instrument. The G4 Instrument operates as a benchtop next generation sequencer designed to produce fast and accurate genetic sequencing results. The PX Instrument combines single cell and spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company was founded by Eli Glezer and Andrew Spaventa in June 2016 and is headquartered in San Diego, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Singular Genomics Systems reports Q1 loss but anticipates G4X launch

Singular Genomics Systems faces financial challenges with negative gross profit and a net loss in Q1 2024, but the G4X spatial sequencer holds promise for addressing spatial sequencing limitations. The company is strategically positioning itself for the commercial launch of G4X in 2025.

Singular Genomics reports revenue growth amidst operational challenges and opportunities

Singular Genomics Systems showed mixed financial performance in Q2 2024, with revenue growth but negative gross profit.
The company's focus on innovation, cost management, and product development positions it for future growth opportunities.
Opportunities in the G4X technology and services program offer potential for revenue expansion and market impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. It develops two integrated solutions: G4 Instrument and PX Instrument. The G4 Instrument operates as a benchtop next generation sequencer designed to produce fast and accurate genetic sequencing results. The PX Instrument combines single cell and spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company was founded by Eli Glezer, David Barker and Andrew Spaventa in June 2016 and is headquartered in San Diego, CA.

LA JOLLA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., a company focused on delivering genomic technologies for the advancement of science and medicine, today announced it will participate in a fireside chat at the UBS Genomics 2.0 and MedTech Innovations Summit, which will be webcast on Wednesday, August 11, 2021 at 3:00 PM Pacific Time. CEO Drew Spaventa and CSO Eli Glezer, founders of Singular Genomics, will present and answer questions about the company.

Singular Genomics Systems, Inc. to Present at the UBS Genomics 2.0 and MedTech Innovations Summit

LA JOLLA, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., a company focused on delivering genomic technologies for the advancement of science and medicine, today reported its second quarter 2021 financial results and highlighted recent operating and corporate achievements. Investors and the general public are invited to view the company's quarterly report, filed today on Form 10-Q with the Securities and Exchange Commission (www.sec.gov).

Singular Genomics Systems, Inc. Announces Second Quarter Financial Results and Operations Update

LA JOLLA, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (“Singular Genomics”), a company focused on delivering genomic technologies for the advancement of science and medicine, today announced the closing of its initial public offering of 11,730,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,530,000 additional shares of common stock, at a public offering price of $22.00 per share.

Singular Genomics Systems, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Centessa Pharmaceuticals PLC

Day One Biopharmaceuticals

Dynamics Special Purpose Corp

FIGS

Flywire Corp

Fifth Wall Acquisition Corp III

Paymentus Holdings

Uber

ZipRecruiter

Zoom Video

Six IPOs raised $1.8 billion ahead of the short holiday week, joined by one direct listing and five SPACs. Returns bounced back after tumultuous trading earlier this month, with the week's deals all finishing above issue.

U.S. IPO Weekly Recap And Week Ahead

LA JOLLA, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (“Singular Genomics”), a company focused on delivering genomic technologies for the advancement of science and medicine, today announced the pricing of its upsized initial public offering of 10,200,000 shares of its common stock at an initial public offering price of $22.00 per share. All of the shares of common stock are being offered by Singular Genomics. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Singular Genomics, are expected to be $224.4 million. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “OMIC” on May 27, 2021. The offering is expected to close on June 1, 2021, subject to the satisfaction of customary closing conditions. In addition, Singular Genomics has granted the underwriters a 30-day option to purchase an additional 1,530,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Singular Genomics Systems, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock

ZipRecruiter, the fourth company this year to go ahead with a direct listing, is leading a slate of seven companies to the public equity markets this week.

ZipRecruiter, Another Direct Listing, Is One of Seven IPOs This Week

News for Singular Genomics Systems Stock (OMIC)